The GLP-1 That Skips the Muscle.

When the first wave of semaglutide trial results came out, the headline number was the weight loss. Around fifteen percent of body weight gone in a year, more in some patients, more again with tirzepatide. The number underneath that headline did not get the same airtime. In the body-composition substudies, where researchers measured what kind of tissue was disappearing, somewhere between a quarter and forty percent of the weight lost was lean mass.¹ Muscle, organ tissue, the parts of the body that hold a person up.

For a healthy thirty-five-year-old, that ratio is unwelcome but survivable. The body rebuilds. For a fifty-five-year-old woman, who is already losing muscle to age and menopause at a rate of around one percent per year,² the same ratio is a different problem. It compounds a clock that was already running.

This is the problem the next generation of these drugs is being engineered around.

What the body actually loses

The simple version is this. A GLP-1 medication works mainly by quieting appetite. The patient eats less, the body enters a caloric deficit, and weight comes off. The catch is that any sustained caloric deficit costs the body some lean mass along with the fat. It is true of dieting. It is true of bariatric surgery. It is true of starvation. The body breaks down what it can spare, and a meaningful amount of what it can spare is muscle.

In the STEP 1 substudy that used DXA scanning to measure body composition, patients on semaglutide lost fat mass and lean mass in roughly the proportions that a long calorie restriction would predict.³ Lean mass made up around forty percent of total weight lost in some analyses, somewhere closer to a quarter in others. The exact figure depends on the protocol and how long the patient stays on the drug. The pattern does not.

What patients feel from this is not always obvious from a number on a scale. It is a softer body. A weaker grip. Slower stairs. A face that looks gaunt because the underlying tissue is also thinning. None of those are aesthetic failures. They are signals that the body is rebuilding itself with less raw material than it had before.

The drug with a third receptor

Eli Lilly's retatrutide is the molecule that has changed the conversation. Semaglutide acts on a single receptor, the one for GLP-1. Tirzepatide, the active ingredient in the second-generation Lilly drugs, acts on two: GLP-1 and GIP. Retatrutide acts on three. The third receptor is for glucagon, a hormone the body uses, among other things, to increase resting energy expenditure. Burning calories at rest, in other words, rather than only restricting them at the table.

In the Phase 2 obesity trial published in The New England Journal of Medicine in 2023, patients on the highest dose of retatrutide lost about twenty-four percent of their body weight by week forty-eight, with most still on the descending slope of the curve.⁴ The headline number was striking. Less remarked on, and probably more important, was the composition data. In the body-composition substudy, the proportion of weight lost that was fat mass was substantially higher than what had been seen with single-receptor GLP-1s. Lean mass came off more slowly than it does on semaglutide.

The mechanism is plausible. If a drug increases resting expenditure in addition to suppressing appetite, the body does not need to break down muscle as aggressively to balance its energy books. Glucagon agonism appears to do exactly that. It is also why retatrutide has its own challenges, including effects on heart rate and on blood sugar regulation, that single-receptor GLP-1s do not have.

The drug that protects the muscle directly

The second approach is to leave the GLP-1 alone and add a separate drug whose only job is to defend lean mass. The leading candidate is bimagrumab, an antibody that blocks the receptor for myostatin and activin, two signaling proteins that normally tell muscle to slow down its growth. Block them, and muscle holds onto more of itself even when the rest of the body is in a deficit.

Bimagrumab on its own caused fat loss and lean-mass gain in a published Phase 2 study in adults with obesity and type 2 diabetes.⁵ The more interesting trials are the ones now running that combine it with semaglutide. The premise is that one drug pulls the fat down, the other keeps the muscle in place. Early read-outs from the BELIEVE program have been positive enough that several investigators have begun describing combination therapy as the likely standard of care within five years.⁶ That timeline is optimistic. The signal is real.

The headline number is the weight loss. The number underneath the headline is the kind of tissue that disappeared with it.

Why this matters more after fifty

Sarcopenia is the medical term for the loss of muscle mass and strength that comes with age. It begins, in most women, somewhere in the early forties and accelerates through menopause. Estrogen does several things for muscle, all of them protective, and when estrogen falls, muscle protein synthesis falls with it.⁷ A fifty-year-old woman already has less muscle than she did at thirty, regardless of how she eats or trains.

Adding a GLP-1 to that trajectory pulls weight down quickly, often the first time a sustainable weight loss has actually been possible. It can also pull muscle down at a rate that, in some studies, looks like an additional five to ten years of aging compressed into twelve months.⁸ The fix in the literature is not to come off the drug. It is to take it with the muscle problem in mind. That means resistance training during the titration window, adequate protein intake, and, in time, a drug that does less collateral damage at the same dose.

What clinicians appear to be doing

The current consensus among endocrinologists writing in this space is unsentimental. The benefits of GLP-1s for cardiometabolic health are large enough that the lean-mass cost is, on balance, worth paying. The shift is in how the cost is managed. Protein recommendations have crept up. Resistance training is being prescribed alongside the medication, rather than suggested as an afterthought. Body-composition scans, not just scales, are entering the standard follow-up.⁹

The longer-term shift is in what gets prescribed. If retatrutide reaches market with the lean-mass profile its Phase 2 data suggests, and if combination therapy with bimagrumab clears its Phase 3 trials, the first-line drug a year from now may not be the first-line drug five years from now. The molecule will be designed around the question the first generation did not address.

Editorial content. Not medical advice. The findings described above come from published trials and meta-analyses; individual response varies. Talk to your prescriber before changing how you take any medication.